09/03/2026
Do you have ROS1-positive non-small cell lung cancer (NSCLC)?
Patient organizations are gathering input from patients with ROS1-positive NSCLC to inform a funding review of taletrectinib in Canada.
We are seeking individuals who have ROS1-positive NSCLC, and are especially interested in connecting with individuals who have accessed taletrectinib, to share their experiences by participating in a confidential 45-minute telephone interview.
Patient perspectives play a critical role in helping decision-makers better understand the real-world impact of cancer and its treatments.
If this applies to you or someone you care for, we encourage you to participate and share your experience.
👉 To learn more or take part, please contact Winky Yau at [email protected]
Your voice can help shape others’ access to this therapy. 💙